Trade-Ideas LLC identified

AbbVie

(

ABBV

) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified AbbVie as such a stock due to the following factors:

  • ABBV has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $681.2 million.
  • ABBV traded 10,830 shares today in the pre-market hours as of 8:00 AM.
  • ABBV is down 5.1% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABBV with the Ticky from Trade-Ideas. See the FREE profile for ABBV NOW at Trade-Ideas

More details on ABBV:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The stock currently has a dividend yield of 3.9%. ABBV has a PE ratio of 32. Currently there are 9 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TST Recommends

The average volume for AbbVie has been 8.6 million shares per day over the past 30 days. AbbVie has a market cap of $95.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.62 and a short float of 1.5% with 1.90 days to cover. Shares are down 1.6% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates AbbVie as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

Highlights from the ratings report include:

  • ABBV's revenue growth has slightly outpaced the industry average of 13.6%. Since the same quarter one year prior, revenues rose by 18.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 144.9% when compared to the same quarter one year prior, rising from $506.00 million to $1,239.00 million.
  • Net operating cash flow has increased to $2,155.00 million or 20.66% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 0.88%.
  • The gross profit margin for ABBVIE INC is currently very high, coming in at 85.04%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, ABBV's net profit margin of 20.84% significantly trails the industry average.
  • ABBVIE INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ABBVIE INC reported lower earnings of $1.09 versus $2.56 in the prior year. This year, the market expects an improvement in earnings ($4.28 versus $1.09).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.